E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To minimize the occurrence of sub-therapeutic and supra-therapeutic C0 of tacrolimus on day 3 after transplantation by basing the starting dose of tacrolimus on a new dosing algorithm, rather than the standard bodyweight-only-based approach. |
|
E.2.2 | Secondary objectives of the trial |
• Whether a tacrolimus starting dose based on the algorithm will lead to more patients being within the tacrolimus target C0 on days 7 and 10 after transplantation compared with previously transplanted patients receiving a standard starting dose of tacrolimus.
• Whether a tacrolimus starting dose based on the algorithm will lead to fewer patients with extremely high or low tacrolimus C0 on day 3 after transplantation
• Whether a tacrolimus starting dose based on the algorithm will lead to a more rapid achievement of tacrolimus target C0
• Whether a tacrolimus starting dose based on the algorithm will lead to a different cumulative tacrolimus dose (mg/kg/day)
• Incidence of BPAR and (serious) adverse events within the first 10 days after transplantation.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Age 2-18 years old
• Patients to be transplanted with a first kidney allograft
• Patients receiving a kidney from a blood group AB0-compatible donor
• Patients who will receive tacrolimus as part of the initial immunosuppressive therapy |
|
E.4 | Principal exclusion criteria |
A potential subject who meets any of the following criteria will be excluded from participation in this study:
• No signed written informed consent.
• Recipients of a non-renal organ transplant at the same occasion
• Recipients of a blood group AB0-incompatible kidney allograft
• Recipients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days.
• Recipients using medication known to have a pharmacokinetic interaction with tacrolimus (clarithromycin, doxycycline, erythromycin, rifampicin, carbamazepine, phenobarbital, phenytoin, amiodarone, diltiazem, verapamil, fluconazole, itraconazole, ketoconazole, HIV protease inhibitors and theophylline).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main study endpoint of the study is the proportion of patients reaching the target C0 (10-15 ng/mL) on day 3. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
3 days after transplantation |
|
E.5.2 | Secondary end point(s) |
Secondary study endpoints of the study are:
• The proportion of patients reaching the target C0 on day 7 and 10.
• The proportion of patients with markedly supra- (>20 ng/mL) or sub-therapeutic (<5 ng/mL) tacrolimus C0 on day 3 after transplantation.
• The time to reach the target C0 (10-15 ng/mL).
• Incidence of biopsy proven acute rejection and (serious) adverse events within the first 10 days after transplantation. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
3, 7 and 10 days after transplantation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |